Navix 75

Clopidogrel is a prodrug that is used to treat blood clots. The irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets suppresses platelet activation and aggregation. Platelet aggregation inhibition is dose-dependent and visible 2 hours after single oral dosages. On the first day, repeated 75 mg doses decrease ADP-induced platelet aggregation, and inhibition achieves a stable state between Days 3 and 7.

Dosage & Administration of Navix 75 Tablet

Acute Coronary Syndrome: In patients who need an antiplatelet effect within hours, initiate clopidogrel with a single 300 mg (4 tablets) oral loading dose and then continue at 75 mg once daily. Initiating it without a loading dose will delay establishment of an antiplatelet effect by several days.

Recent MI, Recent Stroke, or Established Peripheral Arterial Disease: 75 mg once daily orally without a loading dose.

It is given orally with or without food.

Interaction of Navix 75 Tablet

• NSAIDs, warfarin, and selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs, SNRIs): NSAIDs, warfarin, and selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs, SNRIs): CYP2C19 inhibitors (omeprazole or esomeprazole):
• Increases the risk of bleeding. Avoid taking omeprazole or esomeprazole at the same time.
• Repaglinide (substrates for CYP2C8): Clopidogrel should not be taken with Repaglinide since it raises Repaglinide plasma level.

Contraindications

Clopidogrel should not be used if you have any of the following conditions: Hypersensitivity to the medicine or any of the product's components. Peptic ulcer or cerebral hemorrhage are examples of active pathological bleeding.

Side Effects of Navix 75 Tablet

Clopidogrel is generally well-tolerated drug.

• Common side effects: Bleeding, Diarrhoea, gastrointestinal discomfort, hemorrhage, Skin reactions.
• Rare side effects: Acquired hemophilia, anaemia, angioedema, arthralgia, arthritis, bone marrow disorders.

Pregnancy & Lactation

In pregnant women, there are no sufficient and well-controlled trials. It should only be used during pregnancy if absolutely necessary. Clopidogrel is not known to be excreted in human breast milk. Considering the medicine's value to the mother, a decision should be taken whether to quit nursing or discontinue the drug.

Precautions & Warnings

• Clopidogrel should not be used if you have any of the following conditions: Because tA is a prodrug, genetic polymorphisms in CYP2C19 (a poor metabolizer) and medicines that inhibit CYP2C19, such as Omeprazole and Esomeprazole, hinder metabolism to its active metabolite.
• Clopidogrel's antiplatelet action may be reduced if it is taken with certain medications or if you have a CYP2C19 poor metabolizer.
• The risk of bleeding may increase since it inhibits platelet aggregation during the platelet's whole lifetime (7-10 days). Platelet transfusions given within 4 hours of the loading dosage or 2 hours of the maintenance dose may be less efficient in restoring hemostasis.
• The risk of bleeding increases if you stop using Clopidogrel.
• TTP (Thrombotic Thrombocytopenic Purpura) is a type of thrombocytopenic purpura that requires immediate treatment, including plasmapheresis (plasma exchange).
• Patients on clopidogrel or who have a history of hypersensitivity to other thienopyridines have suffered rash, angioedema, or hematologic reactions.

Therapeutic Class

Anti-platelet drugs

Storage Conditions

In a dry environment, keep the temperature below 30°C. Protected from the sun's rays. Do not allow yourself to become frozen. Keep out of children's reach.